81069-02-5

Usage

Uses

Used in Bioconjugation:
3,3'-Dithiobis(sulfosuccinimidylpropionate) is used as a cross-linking agent for bioconjugation purposes. It reacts with amine groups in biomolecules, such as proteins and peptides, to form stable amide bonds, allowing for the covalent attachment of two molecules.
Used in Analytical Chemistry:
3,3'-Dithiobis(sulfosuccinimidylpropionate) is used as a cleavable heterobifunctional cross-linking reagent in analytical chemistry. Its reactivity with sulfhydryl groups allows for the formation of disulfide bonds, which can be cleaved under specific conditions, enabling the monitoring of pyridine-2-thione release at 343 nm.
Used in Drug Delivery Systems:
3,3'-Dithiobis(sulfosuccinimidylpropionate) is used as a cross-linking agent in the development of drug delivery systems. Its ability to form stable amide bonds with amine groups in drug molecules and carriers allows for the controlled release of drugs, improving their bioavailability and therapeutic outcomes.
Used in Material Science:
3,3'-Dithiobis(sulfosuccinimidylpropionate) is used as a cross-linking agent in material science for the synthesis of functional polymers and hydrogels. Its reactivity with amine groups enables the formation of stable covalent bonds, allowing for the development of materials with tailored properties and applications.

Relevant academic research and scientific papers

DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF

The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

NON-HUMAN ANIMAL HAVING HUMAN CD3 GENE SUBSTITUTED FOR ENDOGENOUS CD3 GENE

The present invention provides genetically modified non-human animals which are deficient in at least one or more types of CD3 genes selected from the group consisting of endogenous CD3ε, CD3δ, and CD3γ in its genome and functionally express at least one or more types of human CD3 genes selected from the group consisting of human CD3?, CD3δ, and CD3γ. In the genetically modified non-human animals of the present invention, mature T cell differentiation and production can take place, and immunocompetent cells including T cells can exert their functions. The genetically modified non-human animals of the present invention enable efficient evaluation and screening in the development of therapeutic agents and therapeutic methods that use human CD3-mediated targeted drugs.